Management Of Prostrate Cancer

This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient’s perspective.

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

The statistics are sobering: over 200,000 men in the United States are diagnosed with prostate cancer every year. With this diagnosis, men are expected to psychologically combat the worry, practical concerns, and the emotional and physical changes during an immensely trying time. How to help? In Managing Prostate Cancer: A Guide for Living Better, Dr. Andrew J. Roth, a psychiatrist specializing in psychological support for cancer patients, provides the emotional skills and strategies necessary to help patients deal with the challenges a prostate cancer diagnosis brings to everyday life. These tools, which Dr. Roth terms "Emotional Judo," effectively teach patients to identify what their fears are rooted in, how to distinguish the rational and irrational aspects of their thoughts and behaviors, make healthier choices to promote a more positive approach, and ultimately transform their lives into a more fulfilling and peaceful journey.

Teaches patients with prostate cancer and their loved ones strategies for how to live better with the questions and challenges that arise with this diagnosis.Over 200,000 men in the United States are diagnosed with prostate cancer every year. How they medically combat this disease is up to their medical teams and the latest research. But how they psychologically combat the worry, practical concerns, and all of the changes in their lives? It's up to theindividual himself, as well as family and caregivers, and it is an equally important component in the patient's recovery. Dr. Andrew J. Roth, a psychiatrist who specializes in psychological support for cancer patients, provides the emotional skills and strategies necessary to healthfully deal withthe challenges that a prostate cancer diagnosis brings to daily life. These tools, which Roth terms "Emotional Judo," will also help healthcare givers to provide improved support for their patients and families. For the last twenty years, Dr. Roth has served as the Attending Psychiatrist of theMemorial Sloan Kettering Cancer Center and has helped members of oncology treatment teams practice the best ways to deal with patients' emotional needs.Dr. Roth helps patients at all stages of the disease learn the best ways to accept and adapt to the consequences of their cancer treatment, including the physical complications of urinary, erectile or bowel dysfunction, fatigue, hot flashes, and the demoralizing recurrence of disease aftertreatment. While there are a number of good books that touch on the diagnostic and treatment processes from beginning to end, Dr. Roth's readable and relevant book is the first to focus on the emotional implications of these physiological symptoms and life changes. By focusing on a specificreadership (men with prostate cancer and their loved ones) rather than a broader group, Dr. Roth offers the most effective and tailored tools for coping with any and all aspects of the disease.

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

This volume maintains the successful Current Multidisciplinary Oncology series format. Section I provides a review of fundamental issues including epidemiology, screening and risk reduction, diagnosis and pathologic characterization, staging, and imaging. There is also a chapter on counseling of the high-risk patient. Section II, Treatment of Localized Disease, provides a thorough review of the range of multidisciplinary management options for these patients including a discussion of quality of life impact. Section III, Treatment of Localized Advanced Disease, provides a detailed review of multimodal (medical, surgical, radiologic) therapies. Section IV, Treatment of Advanced Disease, reviews management courses for metastatic disease including the range of novel and experimental agents likely to have major impact on practice. Throughout the volume the emphasis is on multidisciplinary collaboration and decision-making in the management of the prostate cancer patient.

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

This book comprehensively covers application of salvage therapy in reccurrent prostate cancer. Chapters focus on specific issues associated with a range of surgical and oncological management techniques and strategies including hormone therapy, lymphnode dissection, robotic prostatectomy and salvage reirradiation after locoregional failure. Learning objectives, and definitions of keywords are provided to aid the reader develop a thorough understanding of the topic and reinforce the key points covered in each chapter. Salvage Therapy for Prostate Cancer provides a detailed practically applicable guide on how salvage therapy can be utilised in the treatment of prostate cancer. It represents a valuable resource for trainee and practicing urologists, oncologists, and specialist nurses.